Isoniazid
- Generic Name
- Isoniazid
- Brand Names
- Isonarif, Isotamine, Isotamine B, Rifamate, Rifater
- Drug Type
- Small Molecule
- Chemical Formula
- C6H7N3O
- CAS Number
- 54-85-3
- Unique Ingredient Identifier
- V83O1VOZ8L
- Background
Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis.
- Indication
Isoniazid is used for the treatment of all forms of tuberculosis in which organisms are susceptible. It is also used in combination with rifampin and pyrazinamide.
- Associated Conditions
- Active Tuberculosis, Mycobacterium kansasii infection, Late phase Tuberculosis
- Associated Therapies
- -
Fermented Soybean Supplementation Among Active Pulmonary Tuberculosis Patients With Standard Therapy in Indonesia
- Conditions
- Interventions
- First Posted Date
- 2015-09-18
- Last Posted Date
- 2022-06-21
- Lead Sponsor
- University of Giessen
- Target Recruit Count
- 147
- Registration Number
- NCT02554318
The Optimal Duration of Preoperative Anti-tuberculosis Treatment of Spinal Tuberculosis
- Conditions
- Interventions
- First Posted Date
- 2015-06-23
- Last Posted Date
- 2015-06-23
- Lead Sponsor
- Beijing Chest Hospital
- Target Recruit Count
- 400
- Registration Number
- NCT02477852
- Locations
- 🇨🇳
Beijing chest hospital, Beijing, Beijing, China
An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis
- First Posted Date
- 2015-05-27
- Last Posted Date
- 2021-09-29
- Lead Sponsor
- University of Cape Town
- Target Recruit Count
- 154
- Registration Number
- NCT02454205
- Locations
- 🇿🇦
Brooklyn Chest Hospital, Cape Town, Western Cape, South Africa
The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB
- First Posted Date
- 2015-04-06
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- IUATLD, Inc
- Target Recruit Count
- 588
- Registration Number
- NCT02409290
- Locations
- 🇪🇹
Armauer Hanssen Research Institute, Addis Ababa, Ethiopia
🇪🇹St. Peter's Tuberculosis Specializes Hospital, Addis Ababa, Ethiopia
🇬🇪JSC National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia
Assessing PA-824 for Tuberculosis (the APT Trial)
- Conditions
- Interventions
- First Posted Date
- 2014-10-06
- Last Posted Date
- 2023-07-18
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 157
- Registration Number
- NCT02256696
- Locations
- 🇿🇦
University of Cape Town Lung Institute, Cape Town, South Africa
NAT2 Genotyping in Re-challenge Protocol of INH Titration in Patients With Anti-TB Medications-induced Hepatitis
- First Posted Date
- 2014-03-03
- Last Posted Date
- 2014-03-17
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT02076685
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
A Bioequivalence Study of Two Different Dosages of Isoniazid Tablet Formulations in Human Healthy Volunteers
- First Posted Date
- 2014-01-23
- Last Posted Date
- 2014-01-23
- Lead Sponsor
- Oswaldo Cruz Foundation
- Target Recruit Count
- 28
- Registration Number
- NCT02043314
- Locations
- 🇧🇷
Synchrophar - Ass. e Desenv. de Projetos Clínicos Ltda., Campinas, São Paulo, Brazil
High-Dose Isoniazid Among Adult Patients With Different Genetic Variants of INH-Resistant Tuberculosis (TB)
- First Posted Date
- 2013-09-06
- Last Posted Date
- 2023-02-17
- Target Recruit Count
- 282
- Registration Number
- NCT01936831
- Locations
- 🇭🇹
GHESKIO Institute of Infectious Diseases and Reproductive Health (GHESKIO - IMIS) CRS (31730), Port Au Prince, Haiti
🇿🇦TASK Applied Science CRS (31718), Bellville, South Africa
Diagnosis and Treatment of Co-infection With Human Immunodeficiency Virus /Latent Tuberculosis Infection (HIV/TBL)
- Conditions
- Interventions
- First Posted Date
- 2013-06-12
- Last Posted Date
- 2013-06-12
- Lead Sponsor
- Instituto Nacional de Salud Publica, Mexico
- Target Recruit Count
- 100
- Registration Number
- NCT01875952
- Locations
- 🇲🇽
Instituto Nacional de Salud Publica, Mexico, Cuernavaca Morelos, Mexico
🇲🇽Clínica Especializada CONDESA, Mexico City, D.F, Mexico
Phase I Study of Intralesional Bacillus Calmette-Guerin (BCG) Followed by Ipilimumab in Advanced Metastatic Melanoma
- Conditions
- Interventions
- First Posted Date
- 2013-04-23
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- Ludwig Institute for Cancer Research
- Target Recruit Count
- 5
- Registration Number
- NCT01838200
- Locations
- 🇦🇺
Austin Health, LICR Melbourne Austin Branch, Heidelberg, Victoria, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.